Aulos Bioscience, a Larkspur, CA-based immuno-oncology company, raised $20m in Series A extension funding.
Apple Tree Partners (ATP) made the investment.
The company intends to use the funds to advance its lead human monoclonal antibody candidate, AU-007, through its initial Phase 2 clinical study in solid tumor cancers.
Led by Aron Knickerbocker, chief executive officer, Aulos Bioscience is an immuno-oncology company advancing IL-2 therapeutics that direct cancer patients’ immune systems toward killing tumor cells. Matching machine learning from co-founder Biolojic Design (a biotechnology company in Israel specializing in artificial intelligence and computationally designed functional antibodies) with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, is a computationally designed human antibody that leverages IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway.
FinSMEs
01/08/2023